Published: May 05, 2008
New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
BRIDGEWATER, N.J., May 5 /PRNewswire-FirstCall/ -- A new study examining
the dose accuracy of the SoloSTAR(R) disposable insulin pen, prefilled with
Lantus(R) (insulin glargine [rDNA origin] injection) or Apidra(R) (insulin
glulisine [rDNA origin] injection), found the pens accurately delivered all
insulin doses within standard limits defined by the International Organization
for Standardization (ISO). Lantus(R) SoloSTAR(R) was approved by the U.S. Food
and Drug Administration (FDA) on April 25, 2007. Apidra(R) for use in the
SoloSTAR(R) prefilled disposable pen is currently under review at the FDA.
The study, presented on May 2, 2008 at the 43rd Congress of the German Society
for Diabetes (DDG) inMunich, Germany, examined the accuracy of both pens at
multiple target dosages to determine the proportion of doses that fell within
ISO ranges.
"For people with diabetes who use an insulin pen to deliver their insulin,
dose accuracy is essential for their treatment," stated Norbert Hermanns,
Ph.D., director of the Research Institute of the Diabetes Academy Mergentheim,
Bad Mergentheim,Germany, and lead investigator in the study. "Based on the
findings of this study, we concluded that the SoloSTAR(R) pen is an accurate
insulin delivery option for people with diabetes."
The study participants, a random sample of 60 hospital inpatients with
type 1 and type 2 diabetes, were trained on correct use of the SoloSTAR(R)
pen. Participants were then asked to inject three target doses with Lantus(R)
into an insulin-sponge, in doses of 10 (low), 40 (medium) and 80 (high) units,
and three doses of Apidra(R) in doses of 5 (low), 15 (medium) and 30 (high)
units. The quantity of insulin delivered was calculated by the weight of the
insulin pens before and after injection. The order of the dosages was
randomized. All doses (100%) were within the limits prescribed by the ISO
standard (mean doses were only 0.9% to 1.3% below targets for Lantus(R), and
0.4% to 1.1% below targets for Apidra(R)), and the data set was within the
ISO-defined 97.5% confidence intervals at each dose.
About Diabetes
Diabetes is a chronic, widespread condition in which the body does not
produce or properly use insulin, the hormone needed to transport glucose
(sugar) from the blood into the cells of the body for energy. More than 230
million people worldwide are living with the disease and this number is
expected to rise to a staggering 350 million within 20 years. It is estimated
that more than 20 million Americans have diabetes, including an estimated 6.2
million who remain undiagnosed. At the same time, approximately half of those
diagnosed are not achieving the general blood sugar control standard of A1C <7
percent recommended by the American Diabetes Association (ADA). The A1C test
measures average blood glucose levels over a two- to three-month period.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed inParis (EURONEXT: SAN) and inNew York
(NYSE: SNY).
U.S. Contacts:
Carrie Melia
Carrie.Melia@sanofi-aventis.com
908-981-6486
US.GLA.08.05.001
SOURCE sanofi-aventis
Copyright © 2012, PRNewswire
Copyright © 2012, NewsBlaze,
Daily News
Search News
Daily News
